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ABSTRACT
Background and the purpose of the study: As a novel drug in the treatment of cardiac diseases, dl-
praeruptorin A (Pd-Ia) is the major active component of traditional herbal medicine Peucedanum 
praeruptorum Dunn and is metabolized primarily via cytochrome P450 isozymes (CYP) 3A1 
and 3A2 in rats. In the present study, the influence of liver cirrhosis on pharmacokinetics of Pd-
Ia and hepatic mRNA expression of CYP3A1 and 3A2 in rats with experimental liver cirrhosis 
(LC rats) were evaluated. 
Methods: Pd-Ia was given intravenously (5 mg·kg-1) to LC rats induced by dimethylnitrosamine 
and pharmacokinetic variables were measured. Enzyme kinetic metabolism of Pd-Ia in rat 
hepatic microsomes was also investigated and hepatic mRNA expression of CYP3A1 and 3A2 
were measured by real-time PCR.
Results and major conclusion: After intravenous administration in LC rats, the area under the 
plasma concentration-time curve from time zero to infinity (AUC0-∞) was significantly greater 
than that in control rats, which might be due to slower rate of the hepatic blood flow and  be due to slower rate of the hepatic blood flow and  due to slower rate of the hepatic blood flow and slower rate of the hepatic blood flow and  rate of the hepatic blood flow and rate of the hepatic blood flow and of the hepatic blood flow and hepatic blood flow and flow and ow and 
significant slower hepatic intrinsic clearance (CL ficant slower hepatic intrinsic clearance (CL cant slower hepatic intrinsic clearance (CL  hepatic intrinsic clearance (CLint) in rats. The decreased metabolic clearance in rats. The decreased metabolic clearance  The decreased metabolic clearance he decreased metabolic clearance metabolic clearance 
of Pd-Ia in LC rats might be at least partly caused by the decreased levels of CYP3A1 and 3A2 Pd-Ia in LC rats might be at least partly caused by the decreased levels of CYP3A1 and 3A2  LC rats might be at least partly caused by the decreased levels of CYP3A1 and 3A2 rats might be at least partly caused by the decreased levels of CYP3A1 and 3A2  the decreased levels of CYP3A1 and 3A2 
responsible for Pd-Ia metabolism. These findings may provide new insights into the inter- and Pd-Ia metabolism. These findings may provide new insights into the inter- and  metabolism. These findings may provide new insights into the inter- and 
intra-individual pharmacokinetic variability of Pd-Ia.  Pd-Ia. .
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INTRODUCTION
dl-Praeruptorin  A  (Pd-Ia,  Fig  1)  is  the  major 
active  component  of  traditional  herbal  medicine 
Peucedanum  praeruptorum  Dunn  and  has  been 
proved to be a novel Ca2+ influx blocker (1). It has 
been reported that Pd-Ia could inhibit the expression 
of  apoptosis  related  proteins,  reduce  the  level  of 
proinflammatory factors, and increase intermediate 
filament desmin and vimentin contents in ischemia/  in ischemia/ in ischemia/
reperfusion myocardiocytes (2-4). Additionally, Pd-
Ia has been reported to be an effective therapeutic 
drug  for  treatment  of  the  contractile  defects 
associated with cardiac hypertrophy (5). Therefore, 
Pd-Ia has drawn increasing attentions and displayed  has drawn increasing attentions and displayed has drawn increasing attentions and displayed 
bright prospects in prevention and therapy of cardiac 
diseases. 
The  pharmacokinetics,  tissue  distribution  and 
excretion  of  Pd-Ia  in  rats  following  a  single 
intravenous  (i.v.)  administration  have  been 
investigated  by  our  group.  Few  intact  form  of 
Pd-Ia  was  excreted  by  bile  and  kidney,  which 
might be resulted from liver first pass effects (6). 
Moreover, based on in vitro study, liver could be 
the main metabolizing organ and Pd-Ia is primarily 
metabolized via hepatic cytochrome P450 isozymes 
(CYP) 3A1 and 3A2 in rats (not reported). The aim 
of this study was to investigate the influence of liver 
cirrhosis  on  the  pharmacokinetics  of  Pd-Ia  after 
i.v. administration (5 mg·kg-1) to rats induced by 
dimethylnitrosamine.
Drug metabolism by CYP isozymes has important 
clinical consequences because of the possibility of 
reduced drug metabolism and subsequent increased 
plasma  drug  concentrations  in  subjects  with  liver 
dysfunctions (7). Liver cirrhosis is a chronic disease 
with  high  mortality  rate.  An  experimental  liver 
cirrhotic rat model induced by dimethylnitrosamine 
was used in this study, which simulates the clinical 
features of human liver cirrhosis such as mortality, 
ascites,  hepatic  parenchymal  cell  destruction, 
formation  of  connective  tissue  and  nodular 
regeneration  (8).  It  has  also  been  reported  that 
dimethylnitrosamine-induced liver cirrhosis in rats 
is reproducible (9). 
MATERIALS AND METHODS
Materials
Pd-Ia  (purity > 98 %) was kindly donated by (purity > 98 %) was kindly donated by   > 98 %) was kindly donated by > 98 %) was kindly donated by   98 %) was kindly donated by 98  %) was kindly donated by   was kindly donated by was  kindly  donated  by by 
Prof.  Okuyama  T (Meiji College of Pharmacy,   (Meiji College of Pharmacy, Meiji  College  of  Pharmacy, 
Tokyo,  Japan).  Diazepam (purity > 98 %, internal Diazepam (purity > 98 %, internal iazepam (purity > 98 %, internal   (purity > 98 %, internal (purity > 98 %, internal   > 98 %, internal > 98 %, internal   98 %, internal 98  %, internal ,  internal internal 
210standard), dimethylnitrosamine and Tris imethylnitrosamine and Tris®-buffer 
were obtained from Sigma-Aldrich (MO, USA). obtained from Sigma-Aldrich (MO, USA).  from Sigma-Aldrich (MO, USA). Sigma-Aldrich (MO, USA).  (MO, USA). , USA). ). 
Reduced form of β-nicotinamide adenine educed  form  of  β-nicotinamide adenine β-nicotinamide adenine -nicotinamide  adenine 
dinucleotide phosphate (NADPH) was purchased  phosphate (NADPH) was purchased phosphate (NADPH) was purchased 
from  Roche  (Basel,  Switzerland). Detection   Detection 
kits  for  total  proteins,  albumin,  glutamate 
oxaloacetate  transaminase  (GOT),  glutamate 
pyruvate  transaminase  (GPT),  total  bilirubin 
and direct bilirubin were obtained from Nanjing were obtained from Nanjing obtained from Nanjing  from Nanjing 
Jiancheng  Bioengineering  Institute (Nanjing,   (Nanjing, 
China). Other chemicals were of analytical or   Other  chemicals  were  of  analytical  or or 
HPLC grades.
Induction of liver cirrhosis
Male Sprague-Dawley rats (4–5 weeks old, 180–
200 g) were randomly divided into liver cirrhosis 
(LC)  and  control  groups.  Freshly  prepared 
dimethylnitrosamine  (solution in  physiological 
saline)  at  a  dose  of  0.01  mg·kg-1  was  injected 
intraperitoneally to LC rats on three consecutive 
days of the week for 4 weeks (10). For control 
rats,  the  same  volume  of  physiological  saline 
was injected. Experiments were carried out seven 
days after the last dimethylnitrosamine injection 
or physiological saline. 
Preliminary  study  and  real-time  PCR  analysis  of 
CYP3A1 and 3A2
The  serum  of  control  and  LC  rats  (n=5, 
respectively) were collected for the measurement 
of  total  protein,  albumin,  GOT,  GPT,  total 
bilirubin and direct bilirubin. The whole kidney, 
spleen,  and  liver  of  each  rat  were  excised, 
rinsed with physiological saline, blotted dry and 
weighed (10). 
Hepatic total RNA was extracted using the TRIzol  TRIzol TRIzol 
extraction method (Sigma-Aldrich, USA) according 
to  the  manufacturer’s  instructions.  Reverse 
transcription  of  extracted  total  RNA  to  cDNA 
was  performed  using  a  reverse  transcription  kit 
(TaKaRa, Japan). Then, the SYBR Green real-time 
PCR  amplification  and  detection  were  performed 
using the ABI 7500 System (Applied Biosystems, 
USA) and the selective primers for CYP3A1 (sense 
primer: 5’-GAGGCCCAGCTAGAGGGACAACA-
3’,  antisense  primer:  5’-
CGTAGAGGAGCACCAGGACGACT-3’)  (125 
bp),  CYP3A2  (sense  primer:  5’-GGATTCTAA
GCATAAGCACCGAGTG-3’,  antisense  primer: 
5’-GGCCAGGAAATACAAGACAAAGGA
G-3’)  (187  bp),  and  β-actin  (sense  primer:  5'-
CCCTGTGCTGCTCACCGA-3', antisense primer: 
5'-ACAGTGTGGGTGACCCCGTC-3')  (170  bp) 
genes. The cDNA amplifications were carried out in 
a 20 µl reaction volume containing 10 µl of Power 
SYBR® Green master mix, 0.5 µl each of forward 
and reverse primers (10 µmol·l-1), 4 µl of cDNA 
and 5 µl of purified water. Thermal profile for real-
time PCR was 95 °C for 10 min, and 45 cycles at 
95 °C for 15 sec and 60 °C for 1 min, followed by 
the melting curve. The target mRNA levels (n = 4 
for both groups) were normalized with the β-actin 
mRNA level. 
Enzyme kinetic metabolism of Pd-Ia 
Rat  hepatic  microsomes  were  prepared  and 
the  protein  content  was  measured  by  the 
reported methods (11, 12). Microsomal fractions 
(equivalent to 0.5 mg of protein) were mixed with 
50 μl of 0.1 mol·l-1 Tris Tris®-buffer, pH 7.4, containing , pH 7.4, containing 
1 mmol·l-1 NADPH; 5 μl of Pd-Ia (solutions in 
dimethylsulfoxide  at  concentrations  of  5,  10, 
25, 50, 100, 250 and 500 μmol·l-1) and 0.1 mol·l-1 
Tris®-buffer, sufficient to a final volume of 0.5 ml. , sufficient to a final volume of 0.5 ml. 
The reaction mixtures were incubated in a water-bath 
shaker at 37 °C for 3 min, and then terminated by 
placing them on ice. All above incubation conditions 
were linear and Pd-Ia was measured by LC-MS/MS 
(13). The kinetic parameters (Km, Vmax) for the 
disappearance of Pd-Ia were calculated using the 
nonlinear regression method (14). The intrinsic 
clearance  (CLint)  for  the  disappearance  of  Pd-
Ia  per  milligram  of  protein  was  calculated  by 
dividing the Vmax by the Km. 
Pharmacokinetic study of Pd-Ia 
The cannulation of the jugular veinandcarotidartery  andcarotidartery and carotid artery 
was performed for the pretreatment of rats (15). Pd- . Pd-
Ia (solution in PEG400 / Tween80 / physiological solution in PEG400 / Tween80 / physiological  in PEG400 / Tween80 / physiological  / Tween80 / physiological Tween80 / physiological  / physiological 
saline 1:1:8, v/v/v) at a dose of 5 mg·kg   1:1:8,  v/v/v)  at  a  dose  of  5 mg·kg   mg·kg mg·kg ·kg kg-1  was was 
infused via the jugular vein to rats in both groups both groups  groups s 
(n=8,  respectively).  Following administration of Following  administration  of 
Pd-Ia, a blood sample (approximately 0.2 ml) was  a blood sample (approximately 0.2 ml) was 
collected via the carotid artery at 0 (control), 1 (at the 
end of the infusion), 5, 15, 30, 60, 90, 120, 180, 240, 
360 and 480 min. Each blood sample was immediately 
centrifuged  and  a  100  μl  of  supernatant  plasma 
layer was transferred into another tube and stored at                                           
-80 °C until analysis.The 8 hrs bile was collected via  The 8 hrs bile was collected via The 8 hrs bile was collected via 
bile duct cannulation for each rat in both groups. At 
the end of the experiment (24 hrs), each metabolic 
cage was rinsed with 10 ml of distilled water and the 
rinsings were combined with 24 hrs urine. Then each 
rat was sacrificed and the entire gastrointestinal tract 
was removed and homogenated. Concentrations of 
Pd-Ia in the above samples were measured by LC-
MS/MS (13) and pharmacokinetic parameters were 
calculated  using WinNonlin Professional Edition 
Version 2.1 (Pharsight Corporation, USA).
RESULTS AND DISCUSSION
Body weight, organ weight and serum biochemical 
data  in  control  and  LC  rats  are  listed  in  table  1. 
Body weight gain decreased significantly in LC rats 
(from 192 to 274 g) compared with that in control 
rats (from 189 to 372 g). In LC rats, the whole liver 
and kidney weight were lower (55.1% and 17.9% 
decrease, respectively), but the whole spleen weight 
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was  significantly  higher  (52.4%  increase)  than 
those  in  control  rats.  The  liver  weight  based  on 
percentage of body weight was significantly lower 
(39.9% decrease), however, the kidney and spleen 
weight  based  on  percentage  of  body  weight  was 
higher (11.9% and 107.0% increase, respectively) 
in LC rats. Compared with the control rats, the LC Compared with the control rats, the LC LC 
rats had significant decrease in serum levels of total  had significant decrease in serum levels of total  decrease in serum levels of total decrease in serum levels of total serum levels of total  levels of total 
protein  (37.9%) and albumin (33.4%); significant 7.9%) and albumin (33.4%); significant .9%) and albumin (33.4%); significant 9%) and albumin (33.4%); significant %)  and  albumin  (33.4%); significant 3.4%); significant .4%); significant 4%); significant %);  significant 
increased serum levels of GOT (84.5% increase), serum levels of GOT (84.5% increase),  levels of GOT (84.5% increase), 84.5% increase), % increase), 
GPT  (125.7% increase), total bilirubin (289.7%) 125.7% increase), total bilirubin (289.7%) %  increase), total bilirubin (289.7%)   total bilirubin (289.7%) total  bilirubin  (289.7%) 289.7%) %) 
and direct bilirubin (447.8%). The data suggested direct bilirubin (447.8%). The data suggested 47.8%). The data suggested %). The data suggested . The data suggested  The data suggested The data suggested 
that the presence of liver cirrhosis in LC rats was 
apparent.
Cirrhosis  may  alter  drug  disposition  by  a  variety 
of  mechanisms  including  a  reduction  in  absolute 
cell mass with function retained in surviving cells; 
changes  in  the  enzyme  levels  and/or  activity  in 
surviving  hepatocytes;  impaired  drug  entry  into 
hepatocytes; and impaired uptake of oxygen (16).To  To To 
further evaluate the potential mechanisms responsible 
for the metabolism of Pd-Ia in LC rats, changes in 
the hepatic mRNA expression of CYP3A1 and 3A2 
were investigated and are shown in figure 2. The 
hepatic mRNA expression of CYP3A1 and 3A2 in 
LC rats decreased significantly (73.1% and 64.1%, 
respectively), compared with that of control rats.
Table  2  shows  that  the  maximum  velocity  (Vmax) 
for  the  disappearance  of  Pd-Ia  in  LC  rats  was 
significantly slower (63.4% decrease) than that of 
control  rats,  suggesting  that  the  maximal  ability 
to  metabolize  Pd-Ia  in  hepatic  microsomes  was 
significantly slower. However, the Michaelis-Menten 
constant (Km) was not significantly different between 
two groups suggesting that the affinity of Pd-Ia to 
the enzyme(s) was not changed in LC rats. Hence, 
the intrinsic clearance (CLint) for the disappearance 
of Pd-Ia in LC rats was significantly slower (62.8% 
decrease) than that of control rats suggesting that 
metabolism of Pd-Ia could be slower in LC rats.
The mean arterial plasma concentration-time curves 
of Pd-Ia after i.v. administration at a single dose of Pd-Ia after i.v. administration at a single dose of  after i.v. administration at a single dose of 
5 mg·kg mg·kg ·kg kg-1 to control and LC rats are shown in figure 
3, and the relevant pharmacokinetic parameters are 
listed in table 3. After i.v. administration, the mean 
arterial plasma concentrations of Pd-Ia were higher in Pd-Ia were higher in  were higher in 
LC rats, and this resulted in a significant greater AUC0-
∞ (63.5% increase). The terminal half-life half-life (t1/2) in LC 
rats  was  significantly  longer  (67.9%  increase)  and 
the total body clearance (CL) was significantly lower total body clearance (CL) was significantly lower  (CL) was significantly lower 
Parameters Control Liver Cirrhosis
Initial body weight (g) 189±14.4 192±11.5
Final body weight (g) 372±28.2 274±25.6 **
Liver weight (g) 13.8±1.9 6.2±1.5 **
Liver weight (% of body weight) 3.7±0.53 2.2±0.36 **
Kidney weight (g) 2.8±0.29 2.1±0.27 **
Kidney weight (% of body weight) 0.75±0.062 0.79±0.092 *
Spleen weight (g) 0.85±0.077 1.3±0.29 **
Spleen weight (% of body weight) 0.23±0.029 0.47±0.095 **
Serum
Total proteins (g·dl-1) 6.46±0.60 4.01±0.45 **
Albumin (g·dl-1) 3.41±0.49 2.27±0.44 **
GOT (IU·l-1) 99.5±16.3 183.6±21.6 **
GPT (IU·l-1) 45.4±9.8 102.5±22.5 **
Total bilirubin (mg·dl-1) 0.29±0.023 1.13±0.15 **
Direct bilirubin (mg·dl-1) 0.046±0.0095 0.252±0.0554 **
*P < 0.05, **P < 0.01, significant difference compared to control
Table 1. Mean (± SD) body weight, organ weight and serum biochemical data in control and LC rats ( Mean (± SD) body weight, organ weight and serum biochemical data in control and LC rats (n = 5, respectively).
Parameters Control Liver Cirrhosis
Vmax (nmol·min-1·mg protein-1)  59.5±2.8 21.7±2.6 **
Km (μmol·l-1)  238±31.6 233±27.9
CLint (ml·min-1·mg protein-1)  0.25±0.049 0.093±0.0094 **
Vmax: maximum velocity; Km: Michaelis-Menten constant; CLint: intrinsic clearance
**P < 0.01, significant difference compared to control
Table 2. Mean (± SD) kinetic parameters for the disappearance of Pd-Ia in control and LC rats ( Mean (± SD) kinetic parameters for the disappearance of Pd-Ia in control and LC rats ( D) kinetic parameters for the disappearance of Pd-Ia in control and LC rats ( kinetic parameters for the disappearance of Pd-Ia in control and LC rats ( inetic parameters for the disappearance of Pd-Ia in control and LC rats ( in control and LC rats (n = 6, respectively).Zhang et al / DARU 2011 19 (3) 210-215 213
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Figure 1.    The chemical structure of Pd-Ia. 
(46.4% decrease). The total amount of unchanged Pd- Pd-
Iaexcretedin24hrsurine(Ae  excreted in 24 hrs urine (Ae0–24 h, expressed in terms 
of percentage of i.v. dose) were 0.114% and 0.156% 
for control and LC rats, respectively. These results 
indicated  that  the  contribution  of  renal clearance renal  clearance 
(CL CLR) to CL of Pd-IawasalmostnegligibleandtheCL Pd-IawasalmostnegligibleandtheCL  was almost negligible and the CL 
of Pd-Ia could represent nonrenal clearance (CL Pd-Ia could represent nonrenal clearance (CL  could represent nonrenal clearance (CL renal clearance (CL  (CLNR) 
in rats. Moreover, unchanged Pd-Ia recovered from  unchanged Pd-Ia recovered from unchanged Pd-Ia recovered from  Pd-Ia recovered from  recovered from 
the gastrointestinal tract at 24 hrs (GI24 h) was below 
detection limit for both groups; the total amount of 
unchanged Pd-Ia in 8 hrs bile (expressed in terms of Pd-Ia in 8 hrs bile (expressed in terms of  in 8 hrs bile (expressed in terms of 
percentage of i.v. dose) were 0.092% and 0.126% for 
control and LC rats, suggesting that the contribution 
of gastrointestinal and biliary excretion to CLNR of 
Pd-Ia was also negligible. Hence, the CL   was  also  negligible. Hence, the CL   Hence, the CL Hence,  the  CLNR  could 
represent hepatic intrinsic clearance (CLint) of Pd-Ia Pd-Ia 
which was metabolized almost completely after i.v. 
administration.
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Figure 1. The chemical structure of Pd-Ia. Pd-Ia. . figure 2. Hepatic mRNA expression of CYP3A1 and CYP3A2 
in control and LC rats was measured by real-time PCR. Open and control and LC rats was measured by real-time PCR. Open and l and LC rats was measured by real-time PCR. Open and 
hatched columns indicate relative mRNA levels. Each column and 
bar represents mean ± SD for 6 experiments. *P < 0.05, significant 
difference compared to control.
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Parameters Control Liver Cirrhosis
Initial body weight (g) 190±13.4 189±12.5
Final body weight (g) 376±21.6 269±18.6 **
AUC0-∞ (min·μg·ml μg·ml g·ml-1) 68.4±13.9 111.8±29.7 **
t1/2 (min) 59.2±9.0 99.4±10.8 **
CL (ml·min-1) 15.5±2.3 .5±2.3 ±2.3 .3 3 8.3±1.8 **
Vz (l) 1.3±0.26 1.2±0.35
8 h Bile (% of dose) 0.092±0.0033 0.126±0.0060 **
Ae0–24 h (% of dose) 0.114±0.0166 0.156±0.0252 **
GI24 h (% of dose) BDL BDL
AUC0-∞: area under the analyte concentrations versus time curve from time 0 to infinity; t1/2: terminal half-life; CL:totalbodyclearance; L:totalbodyclearance; :totalbodyclearance;  totalbodyclearance; total body clearance; ; 
Vz: terminal volume of distribution;Ae ; Ae0–24 h: urine samples at 24 hrs; GI24 h: gastrointestinal tract samples at 24 hrs
BDL: below the detection limit.
**P < 0.01, significant difference compared to control.
Table 3. Mean (± SD) pharmacokinetic parameters of Pd-Ia after intravenous administration Mean (± SD) pharmacokinetic parameters of Pd-Ia after intravenous administration D) pharmacokinetic parameters of Pd-Ia after intravenous administration  pharmacokinetic parameters of Pd-Ia after intravenous administration pharmacokinetic parameters of Pd-Ia after intravenous administration  parameters of Pd-Ia after intravenous administration parameters of Pd-Ia after intravenous administration  of Pd-Ia after intravenous administration of Pd-Ia after intravenous administration
The AUC0-∞ after i.v. administration of Pd-Ia in LC Pd-Ia in LC  in LC 
rats was significantly higher than that in control rats, 
possibly as a result of the significant slower CL of Pd- Pd-
Ia (Table 3). Since the CL  (Table 3). Since the CLNR of Pd-Ia could represent Pd-Ia could represent  could represent 
its metabolic clearance and Pd-Ia was metabolized Pd-Ia was metabolized  was metabolized 
almost completely after i.v. administration in rats, 
the slower CL could be due to significant slower 
hepatic CLint for the disappearance of Pd-Ia (Table 2) Pd-Ia (Table 2)  (Table 2) 
and slower hepatic blood flow rate (17). The slower 
hepatic  CLint  could  be  at least partly attributed at  least  partly attributed   attributed 
to  significant  decrease  in  mRNA  expression  of 
CYP3A1  and  3A2  compared  with  that  in  control 
rats (Fig 2) since Pd-Ia is primarily metabolized via 
hepatic CYP3A1 and 3A2 in rats. Moreover, it has 
been reported that the protein expression of hepatic 
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Figure 2.    Hepatic mRNA expression of CYP3A1 and CYP3A2 in control and LC rats was 
measured by real-time PCR. Open and hatched columns indicate relative mRNA levels. Each 
column and bar represents mean ± SD for 6 experiments. 
*P < 0.05, significant difference 
compared to control. 
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Figure 2.    Hepatic mRNA expression of CYP3A1 and CYP3A2 in control and LC rats was 
measured by real-time PCR. Open and hatched columns indicate relative mRNA levels. Each 
column and bar represents mean ± SD for 6 experiments. 
*P < 0.05, significant difference 
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CYP3A was decreased in LC rats (18). 
CONCLUSION
The present results suggest that after i.v. he  present  results  suggest that after i.v.   that after i.v. that  after  i.v. .v. 
administration of Pd-Ia at a single dose of 5 mg·kg single dose of 5 mg·kg dose of 5 mg·kg 5 mg·kg-1 
to LCrats,theAUC LC rats,theAUC rats, the AUC AUC0-∞ was significantlygreaterthan ficantlygreaterthan cantly greaterthan  than than 
that of the control rats which could be due to slower of the control rats which could be due to slower  control rats which could be due to slower which could be due to slower  could be due to slower 
hepatic blood flowrateandsignificantslowerhepatic flowrateandsignificantslowerhepatic ow rate and significantslowerhepatic ficantslowerhepatic cant slower hepatic hepatic 
CLint in rats. In addition, the decreased metabolic in rats. In addition, the decreased metabolic metabolic 
clearance  of  Pd-Ia in LC rats might be at least Pd-Ia  in LC rats might be at least   LC  rats might be at least rats  might  be  at  least 
partly caused by the decreased levels of CYP3A1  the decreased levels of CYP3A1 
and 3A2 responsible for Pd-Ia metabolism. These Pd-Ia metabolism. These  metabolism. These 
findings may provide new insights into the inter- 
and intra-individual pharmacokinetic variability of 
Pd-Ia. .
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Figure 3.    Mean (± SD) plasma concentration-time curves of Pd-Ia after intravenous 
administration at a dose of 5 mg·kg
-1 to control rats (Ɣ; n = 8) and LC rats (Ÿ; n = 8). 
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Figure 3.    Mean (± SD) plasma concentration-time curves of Pd-Ia after intravenous 
administration at a dose of 5 mg·kg
-1 to control rats (Ɣ; n = 8) and LC rats (Ÿ; n = 8). 
Figure 3. Mean (± SD) plasma concentration-time curves of Pd-Ia after intravenous administration at a dose of 5 mg·kg-1 to control rats 
(●; n=8) and LC rats (▲; n=8).
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